Pelthos Therapeutics Inc.
Business
Pelthos Therapeutics Inc. is a biopharmaceutical company commercializing FDA-approved topical prescription drugs for dermatology and infectious-disease indications. The company's commercial portfolio includes ZELSUVMI (berdazimer gel) for molluscum contagiosum, XEPI (ozenoxacin cream) for impetigo, and XEGLYZE (abametapir) for head lice. The company operates a manufacturing facility in Durham, North Carolina for active pharmaceutical ingredient production and pursues clinical-stage pain programs targeting the NaV1.7 sodium ion-channel.
Summary from 10-K filed 2026-03-19
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Total revenue | 17 | 0 | — | — | |
| Cost of goods sold | 4 | 0 | — | — | |
| Selling, general and administrative | 42 | 6 | — | — | |
| Research and development | 1 | 1 | 3 | 391,730 | |
| Amortization of intangible assets | 2 | 0 | — | — | |
| Total operating expenses | 49 | 8 | — | — | |
| Operating loss | −32 | −8 | −7 | −2 | |
| Interest expense | −3 | −786,000 | — | — | |
| Impairment of intangible assets | −285,000 | 0 | — | — | |
| Change in fair value of convertible debt | −15 | 0 | — | — | |
| Interest income and other income | 5,000 | 402,000 | — | — | |
| Total other (expense) income | −18 | −384,000 | −518,509 | −140,430 | |
| Net loss before provision for income taxes | −51 | −8 | — | — | |
| Provision for income taxes | −7 | 0 | — | — | |
| Net loss | −43 | −8 | −7 | −2 | |
| Comprehensive loss | −43 | −8 | — | — | |
| Net loss per common share, basic (in dollars per share) | −23.04 | −14.27 | −5.78 | 5.65 | |
| Net loss per common share, diluted (in dollars per share) | −23.04 | −14.27 | −5.78 | — | |
| Weighted average number of common shares outstanding, basic (in shares) | 2 | 557,447 | 1 | 435,312 | |
| Weighted average number of common shares outstanding, diluted (in shares) | 2 | 557,447 | 1 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 18 | 513,000 | — | — | — | |
| Restricted cash, current | 50,000 | 0 | — | — | — | |
| Accounts receivable, net | 9 | 0 | — | — | — | |
| Inventory, net | 24 | 0 | — | — | — | |
| Prepaid expenses and other current assets | 3 | 856,000 | — | — | — | |
| Total current assets | 53 | 1 | 96,391 | 55,074 | — | |
| Property and equipment, net | 10 | 0 | — | — | — | |
| Operating lease right-of-use assets, net | 3 | 0 | — | — | — | |
| Intangible assets, net | 39 | 0 | — | — | — | |
| Goodwill | 25 | 0 | — | — | — | |
| Total assets | 130 | 1 | 96,391 | 55,074 | — | |
| Accounts payable | 3 | 2 | — | — | — | |
| Accrued expenses | 15 | 0 | 645,947 | 221,875 | — | |
| Contingent consideration | 2 | 0 | — | — | — | |
| Operating lease liabilities, current portion | 635,000 | 0 | — | — | — | |
| Deferred revenue, current portion | 966,000 | 0 | — | — | — | |
| Other liabilities | 4 | 0 | — | — | — | |
| Total current liabilities | 26 | 4 | 7 | 4 | — | |
| Operating lease liabilities, net of current portion | 3 | 0 | — | — | — | |
| Deferred revenue, net of current portion | 1 | 0 | — | — | — | |
| Convertible debt | 31 | 0 | — | — | — | |
| Other long-term liabilities | 30 | 0 | — | — | — | |
| Total liabilities | 92 | 4 | 7 | 4 | — | |
| Commitments and contingencies (Note 12) | — | — | — | — | — | |
| Common stock, value | 0 | 0 | 391 | 111 | — | |
| Additional paid in capital | 104 | 19 | 7 | 2 | — | |
| Accumulated deficit | −65 | −21 | −14 | −6 | — | |
| Total stockholders' equity (deficit) | 39 | −3 | −6 | −4 | −4 | |
| Total liabilities and stockholders' equity (deficit) | 130 | 1 | 96,391 | 55,074 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Accretion of interest for royalty obligations | 2 | 0 | — | — | |
| Depreciation of property and equipment | 729,000 | 0 | — | — | |
| Amortization of debt discount | 259,000 | 692,000 | 188,119 | 140,430 | |
| Lease amortization expense | 74,000 | 0 | — | — | |
| Stock-based compensation | 5 | 2 | 2 | 110,146 | |
| Inventory write-off | 1 | 0 | — | — | |
| Gain on default judgment | 0 | −363,000 | — | — | |
| Accounts receivable | −9 | 0 | — | — | |
| Inventory | 2 | 0 | — | — | |
| Prepaid expenses | −880,000 | −861,000 | — | — | |
| Operating lease right-of-use assets | 345,000 | 0 | — | — | |
| Accounts payable | 1 | 1 | — | — | |
| Accrued expenses | 6 | −283,000 | 424,072 | 221,875 | |
| Contingent consideration | 2 | 0 | — | — | |
| Operating lease liabilities | −282,000 | 0 | — | — | |
| Deferred revenue | −589,000 | 0 | — | — | |
| Deferred income tax | −7 | 0 | — | — | |
| Other assets and liabilities | 35,000 | 0 | — | — | |
| Net cash used in operating activities | −23 | −6 | −981,031 | −2 | |
| Purchases of property and equipment | −99,000 | 0 | — | — | |
| Acquisition of LNHC, Inc. | 3 | 0 | — | — | |
| Net cash used in investing activities | −5 | 0 | — | — | |
| Proceeds from PIPE, net | 27 | 0 | — | — | |
| Proceeds from stock option exercises | 206,000 | 0 | — | — | |
| Proceeds from convertible note | 18 | 0 | — | — | |
| Proceeds from loan payable, net of debt discount | 693,000 | 536,000 | 201,008 | — | |
| Payment of loan payable, net of debt discount | −845,000 | −215,000 | — | — | |
| Common stock issued for cash | 0 | 6 | 255,412 | — | |
| Rescission of common stock | 0 | −92,000 | — | — | |
| Repurchase of common stock under stock repurchase plan | 0 | −75,000 | — | — | |
| Shares issued for cash under equity line of credit | 0 | 83,000 | — | — | |
| Net cash provided by financing activities | 45 | 6 | 1 | 2 | |
| Net increase in cash and cash equivalents | 18 | 417,000 | 41,317 | 55,074 | |
| Cash paid for income taxes | 0 | 0 | — | — | |
| Cash paid for interest expense | 19,000 | 0 | — | — | |
| Royalty obligation extinguishment | 369,000 | 0 | — | — | |
| Issuance costs allocated to convertible debt | 1 | 0 | 428,400 | — | |
| PIPE proceeds allocated to accounts payable | 2 | 0 | — | — | |
| PIPE proceeds allocated to debt payable | 20 | 0 | — | — | |
| PIPE proceeds allocated to fees | 600,000 | 0 | — | — | |
| Royalty agreement liability reclassified from additional paid in capital | 11 | 0 | — | — | |
| Debt discount from common stock issued for extension of bridge loan | 0 | 448,000 | — | — | |
| Shares issued for payment of accounts payable or for services | 53,000 | 7,000 | — | — | |
| Conversion of notes to common stock | 737,000 | 1 | — | — | |
| Transfer of liabilities to Chromocell Corporation for Series C Preferred Stock | 0 | 2 | — | — | |
| Shares issued for payment of accrued interest | 0 | 3,000 | — | — | |
| Shares issued for payment of principal on loan payable | 0 | 24,000 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Pelthos Therapeutics Inc.'s CIK number?
Pelthos Therapeutics Inc.'s SEC CIK number is 0001919246 (1919246). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Pelthos Therapeutics Inc.'s SEC filings?
All of Pelthos Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Pelthos Therapeutics Inc. last report earnings?
Pelthos Therapeutics Inc. (PTHS) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001919246-26-000071). This is Pelthos Therapeutics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Pelthos Therapeutics Inc.'s most recent earnings 8-K?
Pelthos Therapeutics Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001919246-26-000071. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Pelthos Therapeutics Inc.'s latest earnings 8-K →
Look up any company's CIK number →